Genmab — April 2015
-
The DuoBody platform represents a novel and elegant post-production technology for the generation of stable bispecific antibodies. This platform is based on the easy-to-use method of controlled Fab-arm exchange and is used to generate bispecific antibodies that retain the biochemical characteristics and quality attributes of regular IgGs. The process has shown to be robust and scalable from bench (μg-mg) to mini bioreactor (mg-g) and manufacturing (kg) production.
-
-
Tak Gentogen.
-
Jeg skriver i Genmabchatten, men min I-pad hakker den over i den forkerte chat nogen gange.
-
136.000 stk har anonyme nu nettosolgt. De købte små 200.000 fredag og mandag.
-
Enig Solsen. Det ser påfaldende ud.
-
525 skulle meget gerne være vendepunktet.
-
Ja Bulder...Der er intet i flukationen som er bekymrende. Vi havde to med pludselige stigninger - og nu falder vi ned til udgangspunktet. Dem som købte inkl. Carneqie sælger igen.
-
to dage
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind